AKT1 and colorectal carcinoma: Recently, Vitiello et al. [112] used four different KRAS-mut CRC cell lines rendered resistant to a combination of cetuximab and refametinib (a selective MEK-inhibitor) and demonstrated that PI3K-AKT pathway activation acts as an escape mechanism in this setting.